Analyzing Oncorus (NASDAQ:ONCR) & Perrigo (NYSE:PRGO)
Analyzing Oncorus (NASDAQ:ONCR) & Perrigo (NYSE:PRGO)
Oncorus (NASDAQ:ONCR – Get Rating) and Perrigo (NYSE:PRGO – Get Rating) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.
安可樂斯(納斯達克代碼：ONCR-GET Rating)和百利高(NYSE：PRGO-GET Rating)都是醫療公司，但哪隻股票更好？我們將根據這兩家公司的盈利能力、估值、收益、分析師建議、風險、機構所有權和股息等方面的實力進行對比。
Institutional and Insider Ownership
機構和內部人持股
65.9% of Oncorus shares are owned by institutional investors. Comparatively, 96.4% of Perrigo shares are owned by institutional investors. 15.9% of Oncorus shares are owned by company insiders. Comparatively, 0.8% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Oncorus 65.9%的股份由機構投資者持有。相比之下，Perrigo 96.4%的股份由機構投資者持有。Oncorus 15.9%的股份由公司內部人士持有。相比之下，Perrigo公司0.8%的股份由公司內部人士持有。強大的機構持股表明，對衝基金、大型基金管理公司和捐贈基金相信，一家公司有望實現長期增長。
Earnings & Valuation
收益與估值
This table compares Oncorus and Perrigo's top-line revenue, earnings per share and valuation.
此表比較了Oncorus和Perrigo的營收、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oncorus | N/A | N/A | -$64.76 million | ($2.96) | -0.15 |
| Perrigo | $4.14 billion | 1.03 | -$68.90 million | ($0.63) | -50.49 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 安科魯斯 | 不適用 | 不適用 | -6,476萬美元 | ($2.96) | -0.15 |
| Perrigo | 41.4億美元 | 1.03 | -6,890萬元 | ($0.63) | -50.49 |
Volatility & Risk
波動性與風險
Oncorus has a beta of 2.24, indicating that its share price is 124% more volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.
Oncorus的貝塔係數為2.24，表明其股價的波動性比標準普爾500指數高124%。相比之下，Perrigo的貝塔係數為0.84，這表明其股價的波動性比標準普爾500指數低16%。
Analyst Ratings
分析師評級
This is a summary of current recommendations and price targets for Oncorus and Perrigo, as provided by MarketBeat.com.
這是MarketBeat.com提供的Oncorus和Perrigo的當前建議和目標價的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oncorus | 0 | 2 | 1 | 0 | 2.33 |
| Perrigo | 0 | 0 | 3 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 安科魯斯 | 0 | 2 | 1 | 0 | 2.33 |
| Perrigo | 0 | 0 | 3 | 0 | 3.00 |
Oncorus currently has a consensus target price of $5.25, indicating a potential upside of 1,090.48%. Perrigo has a consensus target price of $47.33, indicating a potential upside of 48.80%. Given Oncorus' higher probable upside, research analysts clearly believe Oncorus is more favorable than Perrigo.
Oncorus目前的共識目標價為5.25美元，表明潛在上行空間為1,090.48%。Perrigo的一致目標價為47.33美元，表明潛在上行空間為48.80%。鑑於Oncorus更有可能上行，研究分析師顯然認為Oncorus比Perrigo更有利。
Profitability
盈利能力
This table compares Oncorus and Perrigo's net margins, return on equity and return on assets.
下表比較了Oncorus和Perrigo的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Oncorus | N/A | -72.31% | -42.11% |
| Perrigo | -1.93% | 5.31% | 2.47% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 安科魯斯 | 不適用 | -72.31% | -42.11% |
| Perrigo | -1.93% | 5.31% | 2.47% |
Summary
摘要
Perrigo beats Oncorus on 7 of the 13 factors compared between the two stocks.
Perrigo在兩隻股票比較的13個因素中有7個擊敗了Oncorus。
About Oncorus
關於Oncorus
(Get Rating)
(獲取評級)
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Oncorus，Inc.是一家臨牀階段的生物製藥公司，專注於為癌症患者開發病毒免疫療法。該公司的主要候選產品是ONCR-177，這是一種腫瘤內注射的病毒免疫療法，基於其溶瘤的單純皰疹病毒1型平臺，該平臺正處於治療各種癌症的I期臨牀試驗。它還在開發ONCR-GBM，這是一種臨牀前階段的OHSV計劃，用於通過腫瘤內注射治療腦癌；以及基於柯薩奇病毒A21和塞尼卡谷病毒的合成病毒免疫療法。該公司與MSD International GmbH簽署了一項臨牀試驗合作和供應協議，以評估ONCR-177與默克公司的癌症免疫療法KEYTRUDA在實體腫瘤患者的第一階段臨牀試驗中的安全性和耐受性。Oncorus，Inc.成立於2015年，總部位於馬薩諸塞州劍橋市。
About Perrigo
關於Perrigo
(Get Rating)
(獲取評級)
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23 countries, primarily in Europe. The company also offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Perrigo Company plc提供非處方藥(OTC)健康和健康解決方案，通過使消費者能夠預防或治療可以自我管理的疾病來提高個人幸福感。該公司通過兩個細分市場運營，即美國消費者自助服務和國際消費者自助服務。在美國、墨西哥、加拿大和南美，消費者自我護理部門主要專注於商店品牌、各類自我護理產品的開發、製造、營銷和銷售，包括上呼吸道、止痛和助眠產品、消化健康、營養、維生素、礦物質和補充劑、健康生活方式、皮膚護理和個人衞生以及口腔自我護理。該細分市場提供Prevacid 24HR、Good Sense、Zephrex D、Scaraway、Placker、Rbra、Steripod、Firefly、REACH、Dr.Fresh和Burt‘s Bees等品牌的產品。國際消費者自理部門通過一個由藥房、批發商、藥品和雜貨店零售商以及輔助藥房組成的網絡，在大約23個國家和地區(主要是歐洲)開發、製造、營銷和分銷消費者自理品牌。該公司還提供代工服務。Perrigo Company plc成立於1887年，總部設在愛爾蘭都柏林。
Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.
接受Oncorus Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Oncorus和相關公司的最新新聞和分析師評級的每日簡要摘要。